We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.
- Authors
Khademi, M; Bornsen, L; Rafatnia, F; Andersson, M; Brundin, L; Piehl, F; Sellebjerg, F; Olsson, T
- Abstract
Natalizumab affects systemic cytokine expressions and clinical course in relapsing-remitting multiple sclerosis (RRMS). We analyzed levels of inflammatory cytokines in cerebrospinal fluid (CSF) cells and peripheral blood mononuclear cells (PBMCs), levels of matrix metalloproteinase (MMP)-9 and osteopontin (OPN) in CSF, and clinical outcome measures in 22 natalizumab-treated RRMS patients.
- Publication
European journal of neurology, 2009, Vol 16, Issue 4, p528
- ISSN
1468-1331
- Publication type
Journal Article
- DOI
10.1111/j.1468-1331.2009.02532.x